Semaglutide vs Tirzepatide for Weight Loss: A Head-to-Head Clinical Comparison

How Semaglutide and Tirzepatide Work: Two Different Receptor Strategies

Semaglutide activates one hormone receptor. Tirzepatide activates two. That single structural difference explains most of the efficacy gap between them.

Semaglutide is a selective GLP-1 (glucagon-like peptide-1) receptor agonist. Injected once weekly, it reduces appetite through hypothalamic pathways, slows gastric emptying, and stimulates glucose-dependent insulin secretion. The Wegovy FDA label confirms the approved subcutaneous dose for chronic weight management is 2.4 mg once weekly, reached after a 16-week titration [1].

Tirzepatide is classified as a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. GIP receptors are expressed in adipose tissue and may increase energy expenditure while also blunting nausea, which could partly explain why tirzepatide tolerability data look slightly better than expected for its efficacy level. The Zepbound FDA label lists doses from 2.5 mg to 15 mg once weekly [2].

Neither drug is a stimulant. Neither suppresses appetite through adrenergic pathways. Both work by amplifying satiety signals the body already produces, just with different receptor footprints.

Weight Loss Outcomes: What the Key Trials Actually Show

Tirzepatide produces numerically greater weight loss at maximum dose. The difference is clinically meaningful, not just statistically significant.

In STEP-1 (N=1,961 to 68 weeks), adults without diabetes receiving semaglutide 2.4 mg lost a mean of 14.9% of body weight vs 2.4% with placebo [3]. Roughly 86.4% of participants achieved at least 5% weight loss.

SURMOUNT-1 (N=2,539 to 72 weeks) tested tirzepatide in adults without diabetes. Mean weight loss was 15.0%, 19.5%, and 20.9% at the 5 mg, 10 mg, and 15 mg doses, respectively, vs 3.1% with placebo [4]. At the 15 mg dose, 36.2% of participants lost 25% or more of their baseline body weight.

No randomized head-to-head trial between the two agents has been published as of early 2025. The SURMOUNT-5 trial comparing tirzepatide directly to semaglutide 2.4 mg is ongoing. Until those results are available, cross-trial comparisons carry the usual caveats about different populations and study timelines.

Longer-term data are available for both agents. STEP-5 (N=304 to 104 weeks) demonstrated that semaglutide 2.4 mg sustained 15.2% mean weight loss at two years [5]. SURMOUNT-4 showed that patients who withdrew tirzepatide after 36 weeks regained most lost weight within 52 weeks, confirming that chronic use is required for sustained results with either drug [6].

In patients with type 2 diabetes, weight loss is predictably lower for both drugs. STEP-2 (N=1,210) showed semaglutide 2.4 mg produced 9.6% weight loss vs 3.4% with placebo over 68 weeks [7]. SURMOUNT-2 (N=938) reported tirzepatide 10 mg and 15 mg produced mean weight losses of 13.4% and 15.7%, respectively [8].

HealthRX Clinical Decision Framework: Which trial population matches your patient?

| Patient Profile | Best-Matched Trial | Expected Mean Weight Loss | |---|---|---| | No T2D, BMI ≥30 or ≥27 with comorbidity | STEP-1 / SURMOUNT-1 | ~15% sema / ~21% tirz (max dose) | | T2D, BMI ≥27 | STEP-2 / SURMOUNT-2 | ~10% sema / ~16% tirz (max dose) | | After intensive lifestyle program | STEP-3 / SURMOUNT-3 | ~16% sema / ~24% tirz (max dose) | | Long-term maintenance, no T2D | STEP-5 | ~15% at 2 years (sema data only) |

STEP-3 data from JAMA 2021 showed semaglutide 2.4 mg combined with intensive behavioral therapy produced 16.0% mean weight loss at 68 weeks [9]. SURMOUNT-3 showed tirzepatide after a 12-week intensive lifestyle intervention produced 18.4% additional weight loss over 72 weeks, for a total of 24.3% from baseline [10].

Side Effects: Nausea, GI Symptoms, and the Differences That Matter

The side-effect profiles of semaglutide and tirzepatide overlap substantially. Both produce GI symptoms as the dominant adverse events, and both use slow dose titration specifically to reduce their severity.

In STEP-1, nausea occurred in 44.2% of semaglutide participants vs 16.0% with placebo [3]. Vomiting affected 24.8%, diarrhea 29.7%. Most events were mild to moderate and occurred during the titration phase. The Wegovy FDA label lists a discontinuation rate due to adverse events of 7.0% [1].

In SURMOUNT-1, nausea occurred in 33.1% of tirzepatide 15 mg participants, vomiting in 25.2%, diarrhea in 30.3% [4]. Discontinuation due to adverse events was 8.2% at the 15 mg dose [4]. The Zepbound FDA label notes similar patterns across the dose range [2].

Both drugs carry FDA boxed warnings for thyroid C-cell tumors based on rodent data. Neither drug is approved for use in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Gallbladder disease deserves attention. Rapid weight loss of any cause increases gallstone risk, and GLP-1 agents may reduce gallbladder motility directly. STEP-1 reported cholelithiasis in 2.6% of semaglutide participants vs 1.2% with placebo [3]. Tirzepatide trials showed similar rates. Patients with prior biliary disease need counseling before starting either agent.

One potentially clinically relevant difference: tirzepatide participants in SURMOUNT-1 reported slightly lower nausea prevalence at comparable efficacy levels compared to semaglutide in STEP-1, despite greater weight loss. Whether the GIP component genuinely reduces GI burden, or whether this reflects cross-trial population differences, remains unresolved.

Cardiovascular Data: Where Semaglutide Has a Clear Advantage (For Now)

Semaglutide has completed a cardiovascular outcomes trial in people with obesity. Tirzepatide has not.

The SELECT trial (N=17,604) randomized adults with established cardiovascular disease and BMI ≥27 but without diabetes to semaglutide 2.4 mg or placebo. Over a mean follow-up of 39.8 months, semaglutide reduced the rate of major adverse cardiovascular events (MACE) by 20% (HR 0.80 to 95% CI 0.72-0.90, P<0.001) [11]. This is the first data showing a dedicated weight-loss dose of a GLP-1 agent cuts CV events in a non-diabetic population with prior CVD.

The SURMOUNT-MMO trial testing tirzepatide cardiovascular outcomes is ongoing. For now, semaglutide holds an evidence advantage in patients with established atherosclerotic cardiovascular disease. The American Heart Association obesity and cardiometabolic guidelines acknowledge GLP-1 receptor agonists as having cardiovascular outcome benefit, though they were written before SELECT results were fully incorporated [12].

Clinicians treating patients with prior MI, stroke, or peripheral arterial disease currently have stronger evidence supporting semaglutide. This is not a permanent distinction. It reflects timing of trial completion.

Ozempic vs Mounjaro: The Diabetes-Approved Versions Explained

Ozempic and Mounjaro are the diabetes-approved formulations of the same active ingredients in Wegovy and Zepbound. The comparison is straightforward.

Ozempic (semaglutide) is FDA-approved for type 2 diabetes management at doses of 0.5 mg, 1 mg, and 2 mg once weekly. Wegovy (semaglutide 2.4 mg) is approved for chronic weight management. The active ingredient is identical; the approved dose is higher in Wegovy.

Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes at 2.5 mg through 15 mg. Zepbound uses the same dose range but carries FDA approval for obesity and, as of January 2024, for obstructive sleep apnea in adults with obesity. Mounjaro prescribed for weight loss in a patient without diabetes is an off-label use.

Prescribers sometimes write Mounjaro off-label for weight loss when Zepbound supply is constrained, or when a patient's insurance covers the diabetes indication but not the obesity indication. Both brands use the same KwikPen delivery device and the same once-weekly dosing schedule.

Cost, Insurance, and Access in 2024-2025

Price differences between Wegovy and Zepbound are real but narrower than many patients expect.

Wegovy carries a list price of approximately $1,349 per month for the 2.4 mg maintenance dose as of late 2024. Zepbound lists at approximately $1,059 per month for the 15 mg maintenance dose, giving tirzepatide a meaningful list-price advantage of roughly $290 per month.

Both manufacturers offer savings programs. Novo Nordisk's Wegovy savings card can bring out-of-pocket costs to as low as $0 for eligible commercially insured patients. Eli Lilly's Zepbound savings card similarly offers reduced costs for eligible patients. Medicare Part D plans began covering anti-obesity medications more broadly after the Treat and Reduce Obesity Act provisions, though coverage varies significantly by plan formulary.

The AACE/ACE clinical practice guidelines for obesity management recommend comprehensive metabolic management including pharmacotherapy for patients meeting criteria (BMI ≥30, or ≥27 with at least one weight-related comorbidity), but coverage barriers remain the primary access obstacle for most patients [13].

Compounded semaglutide and compounded tirzepatide were widely available during FDA shortage periods. The FDA removed both drugs from its shortage list in 2024, which triggered regulatory action against large-scale compounding facilities. Patients using compounded versions face uncertain supply and lack the safety data from the branded agents' clinical trials.

Who Should Choose Semaglutide Over Tirzepatide (and Vice Versa)

Neither drug is universally superior. The right choice depends on individual clinical context.

Semaglutide may be the better first choice when:

• The patient has established cardiovascular disease (atherosclerotic CVD) and the SELECT CV outcome data are clinically relevant to their management.
• Insurance covers Wegovy but not Zepbound, or prior authorization criteria favor semaglutide.
• The patient has previously tried and tolerated GLP-1 therapy and is already familiar with injection mechanics.
• The prescriber wants two years of maintenance efficacy data (STEP-5 provides this; no equivalent 104-week tirzepatide obesity-indication RCT is yet published).

Tirzepatide may be the better first choice when:

• Maximum weight loss is the primary treatment goal and the patient meets SURMOUNT-1 eligibility criteria (no T2D, BMI ≥30 or ≥27 with comorbidity).
• The patient also has obstructive sleep apnea, since Zepbound holds FDA approval for that indication.
• The patient's insurance covers Zepbound and the lower list price reduces cost-sharing.
• Prior GLP-1 therapy with semaglutide produced inadequate response or intolerable GI side effects (given the possible tolerability difference noted in trial comparisons).

The AACE/ACE guidelines frame anti-obesity pharmacotherapy as part of a chronic disease management model, not a short-term intervention [13]. Whichever agent is chosen, patient and prescriber should agree at the outset that treatment duration is indefinite, contingent on efficacy and tolerability.

Switching From Semaglutide to Tirzepatide

Switching is common in clinical practice and is generally safe, but no large RCT has characterized optimal transition protocols.

The general approach used by obesity medicine specialists involves stopping semaglutide at its current dose, waiting one week (consistent with the weekly dosing interval), and starting tirzepatide at its lowest approved dose of 2.5 mg once weekly. Titration then follows the standard Zepbound schedule: 2.5 mg for 4 weeks, then 5 mg for 4 weeks, continuing upward by 2.5 mg increments every 4 weeks as tolerated, to a maximum of 15 mg.

Restarting at the lowest dose is not optional. Patients sometimes resist because they feel they have already "proven" tolerance to a GLP-1 agent. The GIP receptor component in tirzepatide makes the receptor engagement pharmacologically distinct, and GI side effects can still occur even in patients who tolerated semaglutide without difficulty.

Published case series and real-world prescribing data suggest that most patients who switch from semaglutide to tirzepatide experience continued or improved weight loss. A 2023 real-world analysis of patients switching from GLP-1 monotherapy to tirzepatide reported additional weight loss after the switch, though prospective controlled data are lacking. SURMOUNT-5, the direct head-to-head RCT, may also yield switching-protocol insights when published.

Patients switching for GI intolerance to semaglutide should be counseled that nausea can recur. Starting at 2.5 mg and titrating slowly remains the safest approach.

Dosing Schedules and Titration Side by Side

Both drugs are once-weekly subcutaneous injections. Titration timelines differ.

Semaglutide (Wegovy) titration:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9-12: 1.0 mg once weekly
• Weeks 13-16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance)

Total titration period: 16 weeks to maintenance dose.

Tirzepatide (Zepbound) titration:

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5 mg once weekly
• Weeks 9-12: 7.5 mg once weekly
• Weeks 13-16: 10 mg once weekly
• Weeks 17-20: 12.5 mg once weekly
• Week 21 onward: 15 mg once weekly (maximum dose)

Total titration period: 20 weeks to maximum dose, though many patients are maintained at 10 mg or 12.5 mg based on tolerability and response.

Both agents are injected in the abdomen, anterior thigh, or upper arm. Rotation of injection sites reduces local reactions. Neither requires dose adjustment for mild to moderate renal impairment based on current FDA labeling [1][2].

What the Trials Do Not Tell You: Real-World Gaps

The key trials for both drugs enrolled motivated, protocol-adherent participants with close follow-up. Real-world weight loss typically falls below trial outcomes for almost every intervention in medicine.

STEP-3 tested semaglutide plus intensive behavioral therapy (30 counseling visits over 68 weeks) against placebo plus intensive behavioral therapy. The 16.0% mean weight loss at that frequency of behavioral contact exceeds what most clinical practices can deliver [9]. Most patients in real-world obesity medicine programs see their provider monthly, not biweekly.

Adherence is the single strongest predictor of outcome with either agent. SURMOUNT-4 data make this explicit: tirzepatide withdrawal led to regain of two-thirds of lost weight within 52 weeks [6]. The same pattern appears in STEP-5 withdrawal modeling. Both drugs require continued use to maintain results. Patients who stop for insurance reasons, supply issues, or side effects will regain weight. Prescribers should document this expectation before initiating therapy.

The SELECT trial's cardiovascular benefit was seen across the entire semaglutide-treated group, not just among those who lost the most weight, suggesting that mechanisms beyond weight loss (inflammation, visceral adiposity, endothelial function) contribute to CV risk reduction [11].